SCHEMBL8245489

SCHEMBL8245489

CC(C)Cc1ccc(N2CCN(C)CC2)c(F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.51
▸ ALDH1A1 P00352 3/20 0.45
▸ L3MBTL1 Q9Y468 2/20 0.45
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ MAPT P10636 7/20 0.40
▸ OPRL1 P41146 1/20 0.40
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ POLB P06746 2/20 0.39
▸ RAD52 P43351 1/20 0.39
▸ LMNA P02545 2/20 0.38
▸ TAAR1 Q96RJ0 1/20 0.38
▸ HRH4 Q9H3N8 1/20 0.38
▸ HTR3E A5X5Y0 1/20 0.38
▸ HTR3B O95264 1/20 0.38
▸ HTR3A P46098 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8245474 0.86 ALDH1A1 (0.50) ALDH1A1L3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL8252614 0.84 NPC1 (0.50) ALDH1A1L3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL8427926 0.83 ALDH1A1 (0.49) KDM4EALDH1A1L3MBTL1NPC1RAB9A
SCHEMBL29493267 0.81 ALDH1A1 (0.51) KDM4EALDH1A1L3MBTL1NPC1RAB9A
SCHEMBL14922289 0.81 CHKA (0.50) KDM4EALDH1A1L3MBTL1NPC1RAB9A
SCHEMBL2431131 0.81 ALDH1A1 (0.51) KDM4EALDH1A1L3MBTL1NPC1RAB9A
SCHEMBL14393569 0.80 ALDH1A1 (0.46) KDM4EALDH1A1L3MBTL1NPC1RAB9A
SCHEMBL12127765 0.78 CHKA (0.48) KDM4EALDH1A1L3MBTL1NPC1RAB9A
SCHEMBL13607124 0.78 KDM4E (0.56) KDM4EALDH1A1L3MBTL1NPC1RAB9A
SCHEMBL19194075 0.75 KDM4E (0.48) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7786122-B2 α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-08-31 — — US disclosed
US-20080085894-A1 ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2008-04-10 — — US disclosed
US-7300936-B2 α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085894-A1 ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS APP, APBA1, BACE1 KDM4E 4714/4885ALDH1A1 1197/4885L3MBTL1 3047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback